Literature DB >> 6601133

Presence of circulating anti-idiotype-bearing cells after booster immunization with tetanus toxoid (TT) and inhibition of anti-TT antibody synthesis by auto-anti-idiotypic antibody.

R S Geha.   

Abstract

We have previously documented the appearance of auto-anti-idiotypic (anti-Id) antibody in the serum of normal subjects after booster immunization with tetanus toxoid (TT) antigen. In the present study circulating auto-anti-Id-bearing cells and the regulatory role of auto-anti-Id antibody on anti-TT antibody synthesis were examined. Two adult volunteers were boosted with TT antigen, and IgG (Fab')2 anti-TT was prepared from plasma obtained 7 and 10 days after boosting. Auto-anti-Id antibody directed against autologous IgG (Fab')2 anti-TT became detectable in the serum starting 2 wk and up to 4 mo after booster immunization with TT. Circulating cells capable of specifically binding fluorescein-conjugated autologous IgG (Fab')2 anti-TT were identified starting 3 wk after immunization and throughout the 3- to 4-mo study period. Auto-anti-Id-bearing cells were predominantly B cells and secreted auto-anti-Id antibody after stimulation with pokeweed mitogen (PWM) in vitro. When added to cultures of peripheral blood lymphocytes (PBL) obtained 10 days after immunization, serum auto-anti-Id antibody inhibited the PWM-induced synthesis of IgG anti-TT. This inhibition was idiotype specific and affected predominantly the synthesis of anti-TT idiotypes recognized by the auto-anti-Id antibody. Auto-anti-Id antibody did not affect the synthesis of IgG anti-TT by PBL that co-circulated with the auto-anti-Id antibody. These results suggest that auto-anti-Id antibodies play a role in the regulation of the normal human immune response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601133

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Yeast killer systems.

Authors:  W Magliani; S Conti; M Gerloni; D Bertolotti; L Polonelli
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

3.  Relationship between naturally occurring human antibodies to casein and autologous antiidiotypic antibodies: implications for the network theory.

Authors:  C Cunningham-Rundles; Z K Feng; Z Zhou; K R Woods
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

Review 4.  Premises for immune interventional therapy in rheumatoid arthritis.

Authors:  I R Mackay; M J Rowley
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

5.  Human auto-antiidiotypes regulating T cell-mediated reactivity to tetanus toxoid.

Authors:  A Saxon; E Barnett
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

6.  Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue.

Authors:  Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

7.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

8.  Rabbits immunized with thyroid-stimulating hormone produce autoantiidiotypic thyroid-stimulating antibodies.

Authors:  G N Beall; B Rapoport; I J Chopra; S R Kruger
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Impaired IgG response to tetanus toxoid in human membranous nephropathy: association with HLA-DR3.

Authors:  J Feehally; P E Brenchley; B M Coupes; N P Mallick; D M Morris; C D Short
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

10.  Decline in titers of anti-idiotypic antibodies specific to autoantibodies to GAD65 (GAD65Ab) precedes development of GAD65Ab and type 1 diabetes.

Authors:  Helena Elding Larsson; Ida Jönsson; Ake Lernmark; Sten Ivarsson; Jared R Radtke; Christiane S Hampe
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.